Home Contact Center Add this

Debiopharm Investment S.A.

managing the group's assets

A fully dedicated team to support the sustainable growth of Debiopharm Group.

The main objectives are the preservation of capital of Debiopharm Group, and the generation of regular financial incomes for Debiopharm Group's companies.

Valérie Calvayrac

Valérie Calvayrac

CEO, Debiopharm Investment S.A.

Mrs Calvayrac graduated at the University of Paris (Panthéon-Assas), where she obtained a "Diplôme d'Etudes Supérieures Spécialisées" in Business Law and Tax in 1988 (DESS, currently called "Master II Degree"). She then started a career in the banking sector, and she acquired a broad experience in various positions at Le Crédit Lyonnais (Crédit Agricole Group) in Marketing, Corporate Financing, Retail Banking and Human Resources, before becoming Director of the Financing Department for France, in charge of the Financing for Small Enterprises and of the Real Estate Financing for individuals. She joined Debiopharm Investment SA in April 2008 as General Secretary.

Sophie Genecand

Sophie Genecand

Director, Real Estate department, Debiopharm Investment S.A.

Mrs Sophie Genecand qualified as Architecte HES in 1993 at the Engineering School of Geneva. She started her career at Rampini SA, a general building company based in Geneva, and she carried out a number of architect mandates in the Geneva area. Mrs Genecand then founded and headed the company Immvestis SA of the MK group, a company focused on providing specialist advices in the field of estate expertise and appraisal, and of high yield estates. Mrs Genecand joined Debiopharm Investment in 2010.

Alexandra Le Coz Sanchez

Alexandra Le Coz Sanchez

Director, Private Equity Department, Debiopharm Investment S.A.

Mrs Le Coz Sanchez obtained in 1998 a master II degree from the University of Paris-La Sorbonne: DESS "Information and Decision Techniques in the Enterprise". She has completed her education by becoming a CFA® charterholder. Alexandra has previously worked in different leading multinational companies where she was responsible for Planning, Forecasting and Budgeting. She joined Debiopharm Investment in May 2010 as Financial Analyst. Since 2012, she has headed the Private Equity activities as part of investments diversification strategy. She serves on the Board of Directors of various companies in the portfolio and on some Funds' Advisory Committees.

Samuel Moulin

Samuel Moulin

Chief Investment Officer, Financial department, Debiopharm Investment S.A.

Mr Moulin obtained a BA in International Relations in Geneva in 1991 (IUHEI), completed by a Postgrade Diploma in Economics from the London School of Economics and Political Science in 1993. He received the Federal Diploma for financial analyst and portfolio manager in 1998. He successively worked at Swiss Bank Corporation/UBS, Bank Morgan Stanley and Schroder & Co Banque SA, where he held several leading and strategic positions in investment strategy, asset allocation, portfolio management and financial analysis. He joined Debiopharm Investment in June 2014.

Debiopharm Investment S.A.

Forum "après-demain"
Chemin Messidor 5-7
Case postale 5911
1002 Lausanne
Switzerland

Tel. +41 (0)21 331 29 30
Fax +41 (0)21 331 29 31